DXCMDexcom
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. 10-K, Item 1
- Employees
- 11,100
- Headquarters
- San Diego, CA
- CEO
- Jacob Steven Leach
- Next results
- around Jan 11, 2027
What DXCM's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Facts only; most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans adopted or ended
9 plans still running: Kyle Malady, Jereme Sylvain, Nicholas Augustinos, Sadie Stern, Mark Foletta, Jacob Leach, Jon Coleman, Kevin Sayer, Michael J. Brown.
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Kyle Malady Director |
Adopted 10b5-1 plan | Aug 24, 2026 | up to 3,300 | Aug 24, 2027 | 10-Q Oct 29, 2026 |
The company's descriptionDuring the three months ended September 30, 2026, the following Section 16 officers and directors adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense of Rule 10b5-1(c): Name Title Action Action Date Aggregate Number of Shares to be Sold Expiration Date (1) Kyle Malady Director Adoption 8/24/2026 3,300 8/24/2027 (1) Each trading arrangement permitted or permits transactions through and including the date listed in the table. | |||||
| Jereme Sylvain Executive Vice President, Chief Financial Officer |
Adopted 10b5-1 plan | Jun 10, 2026 | up to 11,571 | Jun 10, 2027 | 10-Q Jul 30, 2026 |
| Nicholas Augustinos Director |
Adopted 10b5-1 plan | Jun 10, 2026 | up to 8,089 | Aug 10, 2027 | 10-Q Jul 30, 2026 |
| Sadie Stern Executive Vice President, Chief People & Culture Officer |
Adopted 10b5-1 plan | May 28, 2026 | up to 30,773 | Aug 26, 2027 | 10-Q Jul 30, 2026 |
| Mark Foletta Lead Independent Director |
Adopted 10b5-1 plan | Mar 13, 2026 | up to 10,000 | Mar 13, 2027 | 10-Q Apr 30, 2026 |
| Jacob Leach President, Chief Executive Officer, and Director |
Adopted 10b5-1 plan | Mar 4, 2026 | up to 33,431 | Mar 4, 2027 | 10-Q Apr 30, 2026 |
| Jon Coleman Executive Vice President, Chief Commercial Officer |
Adopted 10b5-1 plan | Mar 4, 2026 | up to 17,185 | Mar 4, 2027 | 10-Q Apr 30, 2026 |
| Kevin Sayer Executive Chairman |
Adopted 10b5-1 plan | Feb 18, 2026 | up to 107,027 | Feb 18, 2027 | 10-Q Apr 30, 2026 |
| Michael J. Brown Executive Vice President, Chief Legal Officer |
Adopted 10b5-1 plan | Nov 26, 2025 | up to 20,400 | Feb 26, 2027 | 10-K Feb 12, 2026 |
| Jacob S. Leach President, Chief Executive Officer, and Director |
Ended 10b5-1 plan | Nov 7, 2025 | up to 102,732 | Mar 12, 2026 | 10-K Feb 12, 2026 |
| Bridgette P. Heller Director |
Adopted 10b5-1 plan | Aug 14, 2025 | up to 4,048 | Aug 18, 2026 | 10-Q Oct 30, 2025 |
| Richard A. Collins Director |
Adopted 10b5-1 plan | Aug 7, 2025 | up to 6,854 | Aug 10, 2026 | 10-Q Oct 30, 2025 |
| Kyle Malady Director |
Adopted 10b5-1 plan | Jun 6, 2025 | up to 2,885 | Jun 4, 2026 | 10-Q Jul 30, 2025 |
| Steven R. Altman Director |
Ended plan | May 30, 2025 | up to 9,568 | – | 10-Q Jul 27, 2023 |
| Jereme M. Sylvain Executive Vice President, Chief Financial Officer |
Adopted 10b5-1 plan | May 27, 2025 | up to 12,899 | May 27, 2026 | 10-Q Jul 30, 2025 |
| Nicholas Augustinos Director |
Adopted 10b5-1 plan | Mar 14, 2025 | up to 9,333 | Mar 15, 2026 | 10-Q May 1, 2025 |
| Mark G. Foletta Director |
Adopted 10b5-1 plan | Mar 13, 2025 | up to 8,250 | Mar 15, 2026 | 10-Q May 1, 2025 |
| Jacob S. Leach Executive Vice President, Chief Operating Officer |
Adopted 10b5-1 plan | Mar 12, 2025 | up to 102,732 | Mar 12, 2026 | 10-Q May 1, 2025 |
| Michael J. Brown Executive Vice President, Chief Legal Officer |
Adopted 10b5-1 plan | Feb 21, 2025 | up to 31,125 | Feb 20, 2026 | 10-Q May 1, 2025 |
| Sadie M. Stern Executive Vice President, Chief Human Resources Officer |
Adopted 10b5-1 plan | Feb 20, 2025 | up to 22,309 | May 22, 2026 | 10-Q May 1, 2025 |
| Jereme M. Sylvain Executive Vice President, Chief Financial Officer |
Ended 10b5-1 plan | Aug 6, 2024 | up to 10,500 | Aug 6, 2025 | 10-Q Oct 24, 2024 |
| Bridgette P. Heller Director |
Ended plan | Jun 13, 2024 | up to 600 | – | 10-Q Jul 27, 2023 |
| Donald M. Abbey Executive Vice President, Global Business Services, IT Quality and Regulatory Affairs |
Ended plan | May 6, 2024 | up to 3,258 | – | 10-Q Jul 27, 2023 |
| Jacob S. Leach Executive Vice President, Chief Operating Officer |
Adopted 10b5-1 plan | Mar 15, 2024 | up to 102,732 | 365 days | 10-Q Apr 25, 2024 |
| Mark G. Foletta Director |
Adopted 10b5-1 plan | Mar 15, 2024 | up to 6,000 | 365 days | 10-Q Apr 25, 2024 |
| Bridgette P. Heller Director |
Adopted 10b5-1 plan | Feb 25, 2024 | up to 3,352 | 390 days | 10-Q Apr 25, 2024 |
| Matthew Dolan Executive Vice President, Strategy, Corporate Development and Dexcom Labs |
Adopted 10b5-1 plan | Dec 15, 2023 | up to 15,326 | 366 days | 10-K Feb 8, 2024 |
| Michael Brown Executive Vice President, Chief Legal Officer |
Ended 10b5-1 plan | Dec 15, 2023 | up to 14,463 | 367 days | 10-Q Oct 26, 2023 |
| Paul Flynn Executive Vice President, Global Revenue |
Adopted 10b5-1 plan | Dec 15, 2023 | up to 31,253 | 366 days | 10-K Feb 8, 2024 |
| Kevin R. Sayer Chairperson, President and Chief Executive Officer |
Adopted 10b5-1 plan | Dec 12, 2023 | up to 100,965 | 366 days | 10-K Feb 8, 2024 |
| Sadie M. Stern Executive Vice President, Chief Human Resources Officer |
Ended 10b5-1 plan | Dec 12, 2023 | up to 4,708 | 455 days | 10-K Feb 8, 2024 |
| Barry J. Regan Executive Vice President, Global Operations |
Adopted 10b5-1 plan | Dec 4, 2023 | up to 28,430 | 366 days | 10-K Feb 8, 2024 |
| Steven R. Pacelli Executive Vice President and Managing Director, Dexcom Ventures |
Adopted 10b5-1 plan | Nov 27, 2023 | up to 15,000 | 423 days | 10-K Feb 8, 2024 |
| Jereme M. Sylvain Executive Vice President, Chief Financial Officer |
Adopted 10b5-1 plan | Nov 21, 2023 | up to 6,863 | 366 days | 10-K Feb 8, 2024 |
| Girish Naganathan Executive Vice President, Chief Technology Officer |
Adopted 10b5-1 plan | Nov 20, 2023 | up to 5,137 | 366 days | 10-K Feb 8, 2024 |
| Nicholas Augustinos Director |
Adopted 10b5-1 plan | Sep 15, 2023 | up to 7,648 | 366 days | 10-Q Oct 26, 2023 |
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 27, 2023.
Form 144 notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | SADIE STERN Officer |
2,565 | $201,660 | Restricted Stock | adopted May 28, 2026 | 2,565 shares from Oct 27, 2026 |
| Oct 15, 2026 | MICHAEL BROWN Officer |
1,700 | $145,316 | Restricted Stock | adopted Nov 26, 2025 | 1,700 shares from Oct 15, 2026 |
| Sep 28, 2026 | SADIE STERN Officer |
2,565 | $220,975 | Restricted Stock | adopted May 28, 2026 | 5,130 shares from Sep 28, 2026 |
| Sep 15, 2026 | AUGUSTINOS NICHOLAS Director |
6,539 | $549,538 | Vested RSU Grant | adopted Jun 10, 2026 | 6,539 shares from Sep 15, 2026 |
| Sep 15, 2026 | MICHAEL BROWN Officer |
1,700 | $142,868 | Restricted Stock | adopted Nov 26, 2025 | 3,400 shares from Sep 15, 2026 |
| Sep 14, 2026 | AUGUSTINOS NICHOLAS Director |
1,550 | $130,231 | Vested RSU Grant | adopted Jun 10, 2026 | 8,089 shares from Sep 14, 2026 |
| Sep 10, 2026 | JEREME SYLVAIN Officer |
3,638 | $302,936 | Restricted Stock | adopted Jun 10, 2026 | 3,638 shares from Sep 10, 2026 |
| Aug 27, 2026 | SADIE STERN Officer |
2,565 | $226,669 | Restricted Stock | adopted May 28, 2026 | 2,565 shares from Aug 27, 2026 |
| Aug 20, 2026 | KEVIN R SAYER Officer, Director |
26,756 | $2,408,241 | Restricted Stock | adopted Feb 18, 2026 | 26,756 shares from Aug 20, 2026 |
| Aug 14, 2026 | MICHAEL BROWN Officer |
1,700 | $156,281 | Restricted Stock | adopted Nov 26, 2025 | 1,700 shares from Aug 14, 2026 |
| Aug 12, 2026 | Heller Bridgette P Director |
1,012 | $89,349 | Restricted Stock Vesting | adopted Aug 14, 2025 | 1,012 shares from Aug 12, 2026 |
| Aug 3, 2026 | FOLETTA MARK G Director |
2,000 | $170,640 | Vested RSUs | adopted Mar 13, 2026 | 2,000 shares from Aug 3, 2026 |
| Jul 31, 2026 | FOLETTA MARK G Director |
2,000 | $160,000 | Vested RSUs | adopted Mar 13, 2026 | 4,000 shares from Jul 31, 2026 |
| Jul 20, 2026 | KEVIN R SAYER Officer, Director |
26,756 | $2,041,999 | Performance and Restricted Stock | adopted Feb 18, 2026 | 26,756 shares from Jul 20, 2026 |
| Jul 15, 2026 | MICHAEL BROWN Officer |
1,700 | $126,514 | Restricted Stock | adopted Nov 26, 2025 | 3,400 shares from Jul 15, 2026 |
| Jul 6, 2026 | KEVIN R SAYER Officer, Director |
26,756 | $1,926,432 | Performance and Restricted Stock | adopted Feb 18, 2026 | 53,512 shares from Jul 6, 2026 |
| Jun 15, 2026 | FOLETTA MARK G Director |
4,000 | $302,800 | Vested RSUs | adopted Mar 13, 2026 | 4,000 shares from Jun 15, 2026 |
| Jun 15, 2026 | MICHAEL BROWN Officer |
1,700 | $128,435 | Restricted Stock | adopted Nov 26, 2025 | 3,400 shares from Jun 15, 2026 |
| Jun 4, 2026 | JON C COLEMAN Officer |
4,911 | $364,052 | Restricted Stock | adopted Mar 4, 2026 | 4,911 shares from Jun 4, 2026 |
| Jun 3, 2026 | JON C COLEMAN Officer |
4,912 | $358,576 | Restricted Stock | adopted Mar 4, 2026 | 9,823 shares from Jun 3, 2026 |
| May 21, 2026 | KEVIN R SAYER Officer, Director |
26,759 | $1,926,648 | Performance Shares | adopted Feb 18, 2026 | 26,759 shares from May 21, 2026 |
| May 15, 2026 | MICHAEL BROWN Officer |
1,700 | $101,847 | Restricted Stock | adopted Nov 26, 2025 | 1,700 shares from May 15, 2026 |
| May 12, 2026 | Heller Bridgette P Director |
1,012 | $60,730 | Restricted Stock Vesting | adopted Aug 14, 2025 | 1,012 shares from May 12, 2026 |
| Apr 15, 2026 | MICHAEL BROWN Officer |
1,700 | $107,168 | Restricted Stock | adopted Nov 26, 2025 | 1,700 shares from May 15, 2026 |
| Mar 16, 2026 | MICHAEL BROWN Officer |
1,700 | $110,245 | Restricted Stock | adopted Nov 26, 2025 | none found |
| Feb 12, 2026 | Heller Bridgette P Director |
1,012 | $68,826 | Restricted Stock Vesting | adopted Aug 14, 2025 | none found |
| Nov 14, 2025 | Collins Richard Alexander Director |
2,906 | $171,599 | Restricted Stock Vesting | adopted Aug 7, 2025 | none found |
| Nov 12, 2025 | Heller Bridgette P Director |
1,012 | $58,767 | Restricted Stock Vesting | adopted Aug 14, 2025 | none found |
| Nov 10, 2025 | Collins Richard Alexander Director |
3,948 | $217,811 | Restricted Stock Vesting | adopted Aug 7, 2025 | none found |
From the Form 144 XML filed with the SEC, since Nov 10, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Work on DXCM in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DXCM/export.csv") into a cell.